Literature DB >> 19945836

mTOR and cancer: many loops in one pathway.

Alejo Efeyan1, David M Sabatini.   

Abstract

The mammalian target of rapamycin (mTOR) is a master regulator of cell growth and division that responds to a variety of stimuli, including nutrient, energy, and growth factors. In the last years, a significant number of pieces have been added to the puzzle of how mTOR coordinates and executes its functions. Extensive research on mTOR has also uncovered a complex network of regulatory loops that impact the therapeutic approaches aimed at targeting mTOR. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19945836      PMCID: PMC2854285          DOI: 10.1016/j.ceb.2009.10.007

Source DB:  PubMed          Journal:  Curr Opin Cell Biol        ISSN: 0955-0674            Impact factor:   8.382


  58 in total

1.  Role of mTOR in the degradation of IRS-1: regulation of PP2A activity.

Authors:  David Hartley; Geoffrey M Cooper
Journal:  J Cell Biochem       Date:  2002       Impact factor: 4.429

2.  GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR.

Authors:  Do-Hyung Kim; D D Sarbassov; Siraj M Ali; Robert R Latek; Kalyani V P Guntur; Hediye Erdjument-Bromage; Paul Tempst; David M Sabatini
Journal:  Mol Cell       Date:  2003-04       Impact factor: 17.970

3.  Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling.

Authors:  Ken Inoki; Yong Li; Tian Xu; Kun-Liang Guan
Journal:  Genes Dev       Date:  2003-07-17       Impact factor: 11.361

4.  Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action.

Authors:  Kenta Hara; Yoshiko Maruki; Xiaomeng Long; Ken-ichi Yoshino; Noriko Oshiro; Sujuti Hidayat; Chiharu Tokunaga; Joseph Avruch; Kazuyoshi Yonezawa
Journal:  Cell       Date:  2002-07-26       Impact factor: 41.582

5.  Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control.

Authors:  Robbie Loewith; Estela Jacinto; Stephan Wullschleger; Anja Lorberg; José L Crespo; Débora Bonenfant; Wolfgang Oppliger; Paul Jenoe; Michael N Hall
Journal:  Mol Cell       Date:  2002-09       Impact factor: 17.970

6.  PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms.

Authors:  Daniel J Freeman; Andrew G Li; Gang Wei; Heng-Hong Li; Nathalie Kertesz; Ralf Lesche; Andrew D Whale; Hilda Martinez-Diaz; Nora Rozengurt; Robert D Cardiff; Xuan Liu; Hong Wu
Journal:  Cancer Cell       Date:  2003-02       Impact factor: 31.743

7.  A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1.

Authors:  T Haruta; T Uno; J Kawahara; A Takano; K Egawa; P M Sharma; J M Olefsky; M Kobayashi
Journal:  Mol Endocrinol       Date:  2000-06

8.  mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery.

Authors:  Do-Hyung Kim; D D Sarbassov; Siraj M Ali; Jessie E King; Robert R Latek; Hediye Erdjument-Bromage; Paul Tempst; David M Sabatini
Journal:  Cell       Date:  2002-07-26       Impact factor: 41.582

9.  Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway.

Authors:  Brendan D Manning; Andrew R Tee; M Nicole Logsdon; John Blenis; Lewis C Cantley
Journal:  Mol Cell       Date:  2002-07       Impact factor: 17.970

10.  Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1.

Authors:  Christian C Dibble; John M Asara; Brendan D Manning
Journal:  Mol Cell Biol       Date:  2009-08-31       Impact factor: 4.272

View more
  180 in total

1.  Coupled activation and degradation of eEF2K regulates protein synthesis in response to genotoxic stress.

Authors:  Flore Kruiswijk; Laurensia Yuniati; Roberto Magliozzi; Teck Yew Low; Ratna Lim; Renske Bolder; Shabaz Mohammed; Christopher G Proud; Albert J R Heck; Michele Pagano; Daniele Guardavaccaro
Journal:  Sci Signal       Date:  2012-06-05       Impact factor: 8.192

2.  Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance.

Authors:  Kazuhiro Tanaka; Ivan Babic; David Nathanson; David Akhavan; Deliang Guo; Beatrice Gini; Julie Dang; Shaojun Zhu; Huijun Yang; Jason De Jesus; Ali Nael Amzajerdi; Yinan Zhang; Christian C Dibble; Hancai Dan; Amanda Rinkenbaugh; William H Yong; Harry V Vinters; Joseph F Gera; Webster K Cavenee; Timothy F Cloughesy; Brendan D Manning; Albert S Baldwin; Paul S Mischel
Journal:  Cancer Discov       Date:  2011-09-13       Impact factor: 39.397

3.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Authors:  José Baselga; Mario Campone; Martine Piccart; Howard A Burris; Hope S Rugo; Tarek Sahmoud; Shinzaburo Noguchi; Michael Gnant; Kathleen I Pritchard; Fabienne Lebrun; J Thaddeus Beck; Yoshinori Ito; Denise Yardley; Ines Deleu; Alejandra Perez; Thomas Bachelot; Luc Vittori; Zhiying Xu; Pabak Mukhopadhyay; David Lebwohl; Gabriel N Hortobagyi
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

4.  Attenuation of TORC1 signaling delays replicative and oncogenic RAS-induced senescence.

Authors:  Marina Kolesnichenko; Lixin Hong; Rong Liao; Peter K Vogt; Peiqing Sun
Journal:  Cell Cycle       Date:  2012-06-15       Impact factor: 4.534

5.  Tangeretin and its metabolite 4'-hydroxytetramethoxyflavone attenuate EGF-stimulated cell cycle progression in hepatocytes; role of inhibition at the level of mTOR/p70S6K.

Authors:  Z Cheng; S Surichan; K Ruparelia; R Arroo; M R Boarder
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

6.  p62/SQSTM1 Cooperates with Hyperactive mTORC1 to Regulate Glutathione Production, Maintain Mitochondrial Integrity, and Promote Tumorigenesis.

Authors:  Hilaire C Lam; Christian V Baglini; Alicia Llorente Lope; Andrey A Parkhitko; Heng-Jia Liu; Nicola Alesi; Izabela A Malinowska; Darius Ebrahimi-Fakhari; Afshin Saffari; Jane J Yu; Ana Pereira; Damir Khabibullin; Barbara Ogorek; Julie Nijmeh; Taylor Kavanagh; Adam Handen; Stephen Y Chan; John M Asara; William M Oldham; Maria T Diaz-Meco; Jorge Moscat; Mustafa Sahin; Carmen Priolo; Elizabeth P Henske
Journal:  Cancer Res       Date:  2017-05-16       Impact factor: 12.701

Review 7.  N-Methyl-N-nitrosourea as a mammary carcinogenic agent.

Authors:  Ana I Faustino-Rocha; Rita Ferreira; Paula A Oliveira; Adelina Gama; Mário Ginja
Journal:  Tumour Biol       Date:  2015-09-19

8.  eRapa restores a normal life span in a FAP mouse model.

Authors:  Paul Hasty; Carolina B Livi; Sherry G Dodds; Diane Jones; Randy Strong; Martin Javors; Kathleen E Fischer; Lauren Sloane; Kruthi Murthy; Gene Hubbard; Lishi Sun; Vincent Hurez; Tyler J Curiel; Zelton Dave Sharp
Journal:  Cancer Prev Res (Phila)       Date:  2013-11-26

Review 9.  Inflammatory stress and sarcomagenesis: a vicious interplay.

Authors:  Jürgen Radons
Journal:  Cell Stress Chaperones       Date:  2013-08-27       Impact factor: 3.667

10.  Efficacy of rapamycin against glioblastoma cancer stem cells.

Authors:  M Mendiburu-Eliçabe; J Gil-Ranedo; M Izquierdo
Journal:  Clin Transl Oncol       Date:  2013-09-17       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.